Sage Therapeutics (SAGE) PT Lowered to $19 at Goldman Sachs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts SAGE Hot Sheet
Price: $8.68 --0%
Rating Summary:
3 Buy, 25 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 23 | Down: 26 | New: 23
Rating Summary:
3 Buy, 25 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 23 | Down: 26 | New: 23
Join SI Premium – FREE
Goldman Sachs analyst Salveen Richter lowered the price target on Sage Therapeutics (NASDAQ: SAGE) to $19.00 (from $28.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Goldman Sachs upgrades Sirius XM Radio to Buy with $37 target
- CRH plc (CRH) PT Raised to $120 at Truist Securities
- Quanta Services (PWR) PT Lowered to $760 at Jefferies
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
